The Mexican subsidiary of Merck & Co, Merck, Sharp & Dohme, has takenout newspaper, radio and television announcements to warn the Mexican public that counterfeit versions of its injectable Decadron (dexamethasone) are on the market.
The public warning, which has been made in cooperation with the Ministry of Health, does not mention the number of suspected units of the drug which might be on the market. The media announcement told consumers that if they have injectable Decadron in their possession, not to use it, but to return it to the pharmacy immediately.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze